Scarica l'app Stockscreener
100.64
1.70%
-1.74
Pre-mercato:
100.72
0.08
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - Reuters
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Nigeria
Incyte bolsters haematology portfolio in $2bn Vega buyout - Yahoo Finance
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
Incyte to acquire Vega Therapeutics in deal valued at up to $2B - The Business Journals
Incyte to acquire Star subsidiary Vega Therapeutics - The Pharma Letter
Incyte acquires Vega Therapeutics in $1.25 billion deal - grafa.com
Incyte Acquires Vega Therapeutics for $2 Billion, Expanding Hematology Portfolio with Phase 3 Bleeding Disorder Drug VGA039 - Minichart
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders - BioSpace
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B - GuruFocus
Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech - FirstWord Pharma
Incyte to buy company in late stages of development of bleeding control drug - Delaware Business Now
Incyte to buy blood disorder drug in possibly $2B deal - Yahoo Finance
Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset - TradingView
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary - Yahoo! Finance Canada
BRIEF—Incyte eyeing acquisition of Star Therapeutics - The Pharma Letter
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therape - GuruFocus
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therapeutics - GuruFocus
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT (INCY:NASDAQ) - Seeking Alpha
Incyte to buy bleeding disorder drug candidate in deal valued at up to $2 billion - Delaware Business Now
ETFs Investing in Incyte Corporation Stocks - TradingView
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability - ChartMill
Incyte’s sale of Wilmington offices generates just 10 cents in real estate taxes - Spotlight Delaware
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
INCY insider files Form 144 to sell 2,639 shares (INCY) - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - Yahoo Finance
Incyte (INCY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative
Incyte (NASDAQ: INCY) exec has 25,469 shares withheld to cover taxes - Stock Titan
Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus - Bez Kabli
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Citizens maintains Incyte stock rating on pipeline progress By Investing.com - Investing.com Australia
0.05%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):